安罗替尼联合化疗二线对晚期非小细胞肺癌近期疗效、血清肿瘤标记物及炎症因子的影响  

Effects of Arotinib Combined with Second-line Chemotherapy on Short-term Efficacy,Serum Tumor Markers and Inflammatory Factors in Patients with Advanced Non-small Cell Lung Cancer

作　　者：曹俊芝 韩文杰[1] CAO Jun-zhi;HAN Wen-jie(Department of Oncology,Shangqiu First People's Hospital,Shangqiu 476000,Henan Province,China)

机构地区：[1]商丘市第一人民医院肿瘤内科,河南商丘476000

出　　处：《罕少疾病杂志》2024年第11期40-42,共3页Journal of Rare and Uncommon Diseases

摘　　要：目的探讨晚期非小细胞肺癌(NSCLC)患者采用安罗替尼联合化疗二线治疗对近期疗效、血清肿瘤标记物及炎症因子的影响。方法选取2021年10月至2022年9月在商丘市第一人民医院收治的晚期NSCLC患者共计76例,按照随机数字表法分成研究组(n=38)和对照组(n=38),对照组采用化疗二线治疗,研究组采用安罗替尼联合化疗二线治疗,对两组近期疗效、血清肿瘤标记物及炎症因子进行比较。结果研究组客观缓解率(ORR)、疾病控制率(DCR)较对照组更高(P<0.05);两组治疗后血清肿瘤标记物[癌胚抗原(CEA)、血管内皮生长因子(VEGF)、基质金属蛋白酶(MMP9)、细胞角蛋白(CYFRA21-1)]水平降低(P<0.05),研究组水平较对照组更低(P<0.05);两组治疗后炎症因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]水平降低(P<0.05),研究组水平较对照组更低(P<0.05)。结论晚期NSCLC患者采用安罗替尼联合化疗二线治疗可提高近期疗效,改善血清肿瘤标记物及炎症因子水平。Objective To explore the effect of second-line treatment with arotinib combined with chemotherapy on short-term efficacy,serum tumor markers and inflammatory factors in patients with advanced non-small cell lung cancer(NSCLC).Methods A total of 76 patients with advanced NSCLC who were admitted in the First People's Hospital of Shangqiu City from October 2021 to September 2022 were selected,and randomly divided into the study group(n=38,arotinib combined with second-line chemotherapy)and the control group(n=38,the second-line chemotherapy).The short-term efficacy,serum tumor markers and inflammatory factors of the two groups were compared.Results In the objective remission rate(ORR)and disease control rate(DCR),in comparision of the control group,the study group was higher(P<0.05).After treatment,the levels of serum tumor markers[CEA,VEGF,MMP9,CYFRA21-1]in both groups were decreased(P<0.05),and in comparision of the control group,the study group was lower(P<0.05).After treatment,the levels of inflammatory factors[IL-6,TNF-α]were decreased(P<0.05),and in comparision of the control group,the study group was lower(P<0.05).Conclusion The treatment of advanced NSCLC patients with arotinib combined with second-line chemotherapy can improve the short-term efficacy and the level of serum tumor markers and inflammatory factors.

关 键 词：安罗替尼 化疗二线 晚期非小细胞肺癌 血清肿瘤标记物 炎症因子 

分 类 号：R73[医药卫生—肿瘤]